Antibacterial leads from microbial natural products discovery

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 2, 2000, Pages 167-176

  Singh, Maya P ^a   Greenstein, Michael ^a  

^a PFIZER INC   (United States)

Author keywords

Antibacterial; Antibiotic; Natural product; Resistance

Indexed keywords

AGARIDIOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANSAMYCIN DERIVATIVE; ANTIINFECTIVE AGENT; ARENARIC ACID; BE 40665 D; BETA LACTAM ANTIBIOTIC; CYCLOPEPTIDE; DECATROMYCIN A; DECATROMYCIN B; GLYCOPEPTIDE; LINCOSAMIDE DERIVATIVE; LIPOPEPTIDE; LOLOATIN; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SACCHAROMICIN A; SACCHAROMICIN B; STEROID; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TUBELACTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VINYLAMYCIN; VIRIDOMYCIN F;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; REVIEW;

EID: 0033994721     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Davies J In praise of antibiotics. ASM News (1999) 65:304-310. A comprehensive overview of the discovery, development and use of antibiotics in modem medicine. It also discusses the effects of antibiotic usage on the environment, development of antibiotic resistance in bacteria, and ways to counter the antibiotic resistance problem.
2. Demain AL Microbial natural products: Alive and well in 1998. Nature Biotechnol(1998) 16:3-4.
3. Demain AL Stunning achievements of industrial microbiology. ASM News (1999) 65:311 -316.
4. Imada A, Hotta K Historical perspective of approaches to antibiotic discovery. In: Emerging Targets in Antibacterial and Antifungal Chemotherapy. Sutcliffe JA, Georgopapadakou NH (Eds), Chapman and Hall, New York, USA (1992):1 -23.
5. Perlman D (Ed): Structure Activity Relationships Among the Semisynthetic Antibiotics. Academic Press, NY (1977):1-719. Chapters by several authors describing the detailed SAR of penicillins, cephalosporins, aminoglycosides, rifamycins, tetracyclines, lincomycin, actinimycins and coumermycins. By the mid-1970s, about 50,000 semisynthetic antibiotics has been prepared and 1 out of 600 semi-synthetic compounds was successful.
6. Demain AL, Bander RP The -lactam antibiotics: Past, present, and future. Antonie Van Leeuwenhoek Int J Gen Mol Microbiol (1999) 75:5-19.
7. Christopher M, Franco M, Coutinho EL Detection of novel secondary metabolites. Crit Rev Biotechnol (1991) 11:193-276.
8. Yao JD, Moellering RC Antibacterial agents. In: Mannual of Clinical Microbiology. Ballows A (Ed), American Society for Microbiology, Washington DC, USA (1991):1065-1098.
9. Lawrence LE, Pucci MJ, Frosco M, Barren JF: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy of the American Society for Microbiology. Exp Opin Invest Drugs (1999)8:2201-2223.
10. Ganguly AK, McCormick JL, Saksena AK, Das PR, Chan TM Chemical modifications and structure activity studies of ziracin and related everninomicln antibiotics. Bioorg Med Chem Lett (1999) 9:1209-1214.
11. Sum PE, Sum FW, Projan SJ Recent developments in tetracycline antibiotics. CurrPharm Design (1998) 4:119-132.
12. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Test RT In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-MDUtylglycylamido derivative of minocycline (GAR936). Antimicrob Agents Chemother(1999) 43:738-744.
13. Setti EL, Micetich RG New trends in antimicrobial development. Curr Med Chem (1998) 5:101-113.
14. Bryskier A New research in macrolides and ketolides since 1997. Exp Opin Invest Drugs (1999) 8:1171-1194.
15. Rodriguez MJ, Snyder NJ, Zweifel MJ, Wilkie SC, Stack DR, Cooper RD, Nicas Tl, Müllen DL, Butler TF, Thompson RC Novel glycopeptide antibiotics: W-alkylated derivatives active against vancomycin-resistant enterococci. J Antibiot (1998)51:560-569.
16. Zhu J Recent developments in reversing glycopeptideresistant pathogens. Exp Opin Ther Pat (1999) 9:1005-1019.
17. 1999 Physicians' Desk Reference, 53rd Edition. Medical Economics Company, Montvale, NJ, USA (1999).
18. Cheng SS Worldwide sales of prescription pharmaceuticals to 2002. Spectrum (1999) 2:1-16.
19. Market analysis from decision resources Emerging antibacterial agents. Scnp(1999):1129.
20. Pucci MJ, Dougherty TJ, Barrett JF: Why are there no new antibiotics? Exp Opin Invest Drugs (1998) 7:1233-1235.
21. Chopra I, Hodgson J, Metcalf B, Poste G The search for antibacterial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother (1997) 41:497-503.
22. Barbachyn MR, Brickner SJ, Gadwood RC, Garmon SA, Grega KG, Hutchinson DK, Munesada K, Reischer RJ, Taniguchi M, Thomasco LM, Toops DS, Yamada H, Ford CW, Zurenko GE Design, synthesis, and evaluation of novel oxazolidinone antibacterial agents active against multidrug-reslstant bacteria. Adv Exp Med Biol (1998) 456:219-238.
23. Omura S Philosophy of new drug discovery. Microbiol Rev (1986)50:259-279.
24. Bull AT, Goodfellow M, Slater JH Biodiversity as a source of innovation in biotechnology. Annu Rev Microbiol (1992) 46:219-252.
25. Yarbrough GG, Taylor DP, Rowlands RT, Crawford MS, Lasure LL Screening microblal metabolites for new drugs theoretical and practical issues. J Antibiot (1993) 46:535-544. Discussed are the organizational issues and technical aspects of the laboratory operations for an effective microbial metabolitescreening program.
26. Okeke IN, Lamikanra A, Edelman R Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis (1999)5:18-27.
27. Cristino JM Correlation between consumption of antimicrobials in humans and development of resistance in bacteria. Int J Antimlcrob Agents (1999) 12:199-202.
28. Cooksey RC Mechanism of resistance to antimicrobial agents. In: Manual of Clinical Microbiology. American Society for Microbiology, Washington DC, USA (1991 ):1099-1104.
29. Martinez JL, Alonso A, Gomez-Gomez JM, Baquero F Quinolone resistance by mutations In chromosomal gyrase genes. Just the tip of the iceberg? J Antimicrob Chemother (1998) 42:683-688.
30. Thomson CJ The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: A 10 year perspective. J Antimicrob Chemother (1999)43(SupplA):31-40.
31. Takizawa T, Hasimoto K, Itoh N, Yamashita S, Owen K A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats. Hum Exp 7bx/co/(1999) 18:38-45.
32. Glaxo withdraws grepafloxacin worldwide. Scrip (1999) 1028.
33. Jack DB Drug-resistant bacteria: Responding to the infectious disease crisis. Mol Med Today (1996) 2:499-502.
34. Silver LL, Bostian KA Discovery and development of new antibiotics: The problem of antibiotic resistance. Antimicrob Agents Chemother (1993) 37:377-383.
35. Mevius DJ, Sprenger MJ, Wegener HC The microbial threat. Int J Antimicrob Agents (1999) 11:101 -105.
36. Perl TM The threat of vancomycin resistance. Am J Med (1999) 106:526-837.
37. Vining LC Functions of secondary metabolites. Annu Rev Microbiol (1990) 44:395-427.
38. Spéciale A, La Ferla K, Caccamo F, Nicoletti G Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum. Int J Antimicrob Agents (1999) 13:21-28.
39. Li T, Zhang X, Oliver N, Andrew T, Silverman JA, Oleson FB, Tally FP Daptomycin efficacy against vancomycinresistant Enterococcus faecalis (VRE) induced pyelonephritis in the mouse. ICAAC (1999) 39:Abs 1003.
40. Romano G, Berti M, Goldstein BP, Williams R The effect of ramoplanin coating on colonization by Staphylococcus aureus of catheter segments implanted subcutaneously in mice. JAntimicrob Chemother (1997) 39:659-661.
41. Landman D, Quäle JM, Bumey S, Kreiswirth B, Willey BM Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin. JAntimicrob Chemother(1996) 37:323-329.
42. Rolston KV, Dholakia N, Ho DH, LeBlanc B, Dvorak T, Streeter H In vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against Gram-positive clinical isolates from cancer patients. J Antimicrob Chemother (1996) 38:265-269.
43. Grafe U, Mikami Y Novel drugs from microorganisms. In: Drug Discovery from Nature. Grabley S, Thiericke R (Eds), Springer-Verlag, New York, NY, USA (1999):181-301.
44. Labischinski H, Johannsen L New antibiotics with novel mode of action. In: Drug Discovery Nature. Grabley S, Thiericke R (Eds), Springer, Berlin, Germany (1999):302-310.
45. Bush K Antimicrobial agents. Curr Opin Chem Biol (1997) 1:169-175.
46. Singh MP, Zaccardi J, Greenstein M LL-49F233ot, a novel antibiotic produced by an unknown fungus: Biological and mechanistic activities. JAntibiot (1998) 51:1109-1112.
47. Abbanat DA, Singh MP, Greenstein M Hongoquercins, new antibacterial agents from the fungus LL-23G227: fermentation and biological activity. J Antibiot (1998) 51:708-714.
48. Singh MP, Menendez AT, Petersen PJ, Ding WD, Maiese WM, Greenstein M Biological and mechanistic activities of phenazine antibiotics produced by culture LL-141352. J Antibiot (1997) 50:785-787.
49. Singh MP, Mroczenski-Wildey MJ, Steinberg DA, Andersen RJ, Maiese WM, Greenstein M Biological activity and mechanistic Studies of andrimid. JAntibiot(1997) 50:270-273.
50. Beman VS, Greenstein M, Maiese WM Marine microorganisms as a source of new natural products. Adv Appl Microbiol (1997) 43:57-90.
51. Sponga F, Cavaletti L, Lazzarini A, Borghi A, Ciciliato I, Losi D, Marinelli F Biodiversity and potentials of marine-derived microorganisms. J Biotechnol (1999) 70:65-69.
52. Yoshikawa K, Takadera T, Adachi K, Nishijima M, Sano H Korormicin, a novel antibiotic specifically active against marine Gram-negative bacteria, produced by a marine bacterium. JAntibiot(1997) 50:949-953.
53. Horikawa M, Noro T, Kamei Y In vitro anti-methicillinresistant Staphylococcus aureus activity found in extracts of marine algae indigenous to the coastline of Japan. J Antibiot (1999) 52:186-189.
54. Singh MP, Petersen PJ, Weiss WJ, Kong F, Greenstein M Saccharomycins, novel heptadecaglycoside antibiotics produced by Saccharothrix espanaensis: Antibacterial and mechanistic activities. ICAAC (1999) 39:Abs 1807.
55. Igarashi M, Shida T, Sasaki Y, Kinoshita N, Naganawa H, Hamada M, Takeuchi T Vinylamycin, a new depsipeptide antibiotic, from Streptomyces sp. J Antibiot (1999) 52:873879.
56. Momose I, linuma H, Kinoshita N, Momose Y, Kunimoto S, Hamada M, Takeuchi T Decatromicins A and B, new antibiotics produced by Actinomadura sp MK73-NF4. I. Taxonomy, Isolation, physicochemical properties and biological activities. J Antibiot (1999) 52:781-786.
57. Berg A, Zipper H, Dorfelt H, Walter G, Grafe U Agaridiol, a new 1-arylpropane-1,2-diol produced by Agaricus sp. J Basic Microbiol (1999) 39:213-215.
58. Tsukamoto M, Nakajima S, Murooka K, Suzuki H, Hirayama M, Egawa M, Kondo H, Kojiri K, Suda H BE-40665D, a new antibacterial antibiotic produced by an Actinoplanes sp. J Antibiot (1999) 52:178-181.
59. Cheng XC, Jensen PR, Fenical W Arenaric acid, a new pentacyclic polyether produced by a marine bacterium (Actinomycetales). J Nat Products (1999) 62:605-607.
60. Omura S, Enomoto Y, Shinose M, Takahashi Y, Iwai Y, Shiomi K Isolation and structure of a new antibiotic viridomycin F produced by Streptomyces sp K96-0188. J Antibiot (1999) 52:61-64.
61. Gérard JM, Haden P, Kelly MT, Andersen RJ Loloatins A-D, cyclic decapeptide antibiotics produced in culture by a tropical marine bacterium. J Nat Products (1999) 62:80-85.
62. Narve M Application of combinatorial chemistry to antimicrobial drug discovery. Exp Opin Invest Drugs (1998) 7:1257-1271.
63. Ng S, Goodson B, Ehrhardt A, Moos WH, Siani M, Winter J Combinatorial discovery process yields antimicrobial peptoids. Bioorg Med Chem (1999) 7:1781-1785. • N-alkylated glycine trimers are generically referred to as peptoids. Screening of the optimization library for antimicrobial activity identified a single pool of peptoids with activity against both S aureus and E coll. The active peptoids from this pool were active against drug-sensitive and drug-resistant organisms and represent novel antibacterial compounds.
64. Sofia MJ, Allanson N, Hatzenbuhler NT, Jain R, Kakarla R, Kogan N, Liang R, Liu D, Silva DJ, Wang H, Gange D, Andersen J, Chen A, Chi F, Dulina R, Huang B, Kamau M, Wang C, Baizman E, Branstrom A, Bristol N, Goldman R, Han K, Longley C, Axelrod HR, Midha S Discovery of novel disaccharide antibacterial agents using a combinatorial library approach. J Med Chem (1999) 42:3193-3198.
65. Henkel T, Brunne RM, Müller H, Reichel F Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed Engl (1999) 38:643-647.
66. Galperin MY, Koonin EV Searching for drug targets in microbial genomes. Curr Opin Biotechnol (1999) 10:571-578.
67. Moir DT, Shaw KJ, Hare RS, Vovis GF Genomics and antimicrobial drug discovery. Antimicrob Agents Chemother (1999)43:439-446.
68. Bentley R, Bennett JW Constructing polyketides: From collie to combinatorial biosynthesis. Annu Rev Microbiol (1999)53:411-446. References to patent literature
69. MICROBIAL CHEMISTRY RESEARCH FOUNDATION (Takeuchi T, Igarashi M, Osanawa H, Hamada M) Antibiotic tubelactomicin and its production. JP-11217382 (1998).
70. WISCONSIN ALUMNI RESEARCH FOUNDATION (Handelsman J, Goodman RM, Rondon MR, Michelle R) Microorganism genomics, compositions and methods related thereto. WO-09920799(1999).